About Eukaryotic translation initiation factor 5
Eukaryotic translation initiation factor 5 (EIF5) is a protein
from Homo sapiens identified by UniProt accession
P55010, 431 residues long.
MolForge cross-references it against 0 known binders and
44 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 5 |
| UniProt accession | P55010 |
| Gene | EIF5 |
| Organism | Homo sapiens |
| Length | 431 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (44)
Diseases linked to this target (Open Targets).
- Immature Reticulocyte Fraction Measurement · score 0.32
- eosinophil count · score 0.31
- reticulocyte count · score 0.29
- reticulocyte measurement · score 0.29
- risky sexual behaviour measurement · score 0.22
- pancreatic adenocarcinoma · score 0.16
- cyst · score 0.07
- neutrophil percentage of leukocytes · score 0.05
- lean body mass · score 0.03
- axial length measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P55010-F1 | alphafold | PREDICTED | 73.20 | — |
Amino-acid sequence (431 residues)
MSVNVNRSVS DQFYRYKMPR LIAKVEGKGN GIKTVIVNMV DVAKALNRPP TYPTKYFGCE LGAQTQFDVK NDRYIVNGSH EANKLQDMLD GFIKKFVLCP ECENPETDLH VNPKKQTIGN SCKACGYRGM LDTHHKLCTF ILKNPPENSD SGTGKKEKEK KNRKGKDKEN GSVSSSETPP PPPPPNEINP PPHTMEEEED DDWGEDTTEE AQRRRMDEIS DHAKVLTLSD DLERTIEERV NILFDFVKKK KEEGVIDSSD KEIVAEAERL DVKAMGPLVL TEVLFNEKIR EQIKKYRRHF LRFCHNNKKA QRYLLHGLEC VVAMHQAQLI SKIPHILKEM YDADLLEEEV IISWSEKASK KYVSKELAKE IRVKAEPFIK WLKEAEEESS GGEEEDEDEN IEVVYSKAAS VPKVETVKSD NKDDDIDIDA I
Explore Eukaryotic translation initiation factor 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets